Trial Profile
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CrisAd CORE 2
- Sponsors Anacor Pharmaceuticals; Pfizer
- 01 Jan 2024 Results of post hoc pooled analysis from NCT02118766 and NCT02118792, assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with (a) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or (b) topical corticosteroids (TCSs) or TCIs or (c) who were treatment-naive , published in the Dermatitis
- 22 Feb 2023 Results of an analysis impact of crisaborole on sleep outcomes in pediatric patients atopic dermatitis from three clinical studies: CORE-1, CORE-2 and CrisADe CARE 1 study published in the Dermatology and Therapy
- 16 Mar 2022 Results of post-hoc pooled analysis of two studies (AD-301: NCT02118766; AD-302: NCT02118792) assessing efficacy and safety of crisaborole ointment for the treatment of mild-to-moderate atopic dermatitis in pediatric patients, published in the Pediatric Drugs.